News|Videos|November 20, 2026

SOHO-01: Updated efficacy and safety of sevabertinib in advanced HER2-mutant NSCLC, including first-line patients (pts) and those with active brain metastases

The SOHO-01 study evaluated the efficacy and safety of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer across multiple cohorts.

The SOHO-01 study evaluated the efficacy and safety of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer across multiple cohorts. Results showed durable antitumor activity and manageable safety profiles in both previously treated and treatment-naive patients. Additionally, the therapy demonstrated intracranial activity in patients presenting with active brain metastases.


Related to this article